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aim of this study is to present one center experience in pediatric pacing including implantation pro-
cedures and long-term outcome.
Methods and results: During the period from 1996 to 2010, we collected the data of 32 children (18
males) with a mean age of 5.7 ± 3.8 years that underwent permanent pacemaker (PPM) implanta-
tion. Their mean weight was 21.6 ± 13.8 kg, and median body surface area (BSA) was 0.7 m2.
Twenty-ﬁve patients (78.1%) had congenital heart disease (CHD). Pacing was done via subclavian
vein puncture while epicardial pacing was done via standard surgical techniques. All patients were
followed up for 0.25–14 years (median: 2.5 years). Suboptimal pacing parameters were deﬁned by
one or more of the following: R/P wave malsensing, pacing threshold >2 V, or battery longevity
of <1 year. The ﬁrst PPM was endocardial in 21 patients (65.6%) and epicardial in 11 patients
(34.4%). VVI PPMs were implanted in 8 cases (25%), VVIR in 20 cases (62.5%) and DDD in 4
cases (12.5%). A total of 46 procedures were done during the period of study, and total of 44 pulse
generators and 46 leads (31 endocardial) were implanted. Fourteen patients (43.7%) required
2nd ± 3rd procedures. During follow up, suboptimal pacing parameters or pacing system failure
were reported in 12 patients (37.5%) who had signiﬁcantly lower age, weight and BSAm (R. Samir).
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184 R. Samir et al.(P= 0.048, 0.023, and 0.032, respectively). The overall battery survival was 60% at 125 months,
and ventricular lead survival was 63% at 125 months, with no signiﬁcant difference in survival
between epicardial and endocardial leads (P> 0.05).
Conclusion: Permanent pacing in pediatric age group is relatively safe. However, there is substan-
tial higher incidence of suboptimal pacing parameters and pacing system failures especially in youn-
ger and smaller children. Epicardial steroid eluting leads are comparable to endocardial steroid
eluting leads in performance.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Permanent pacemakers (PPMs) have a growing use in pediatric
population due to congenital and surgically acquired rhythm
disturbances, but they present unique problems and implica-
tions for their implantation and follow-up. The diversity and
complexity of pediatric patients and congenital heart disease
make device management a highly individualized art. In pedi-
atric pacing there are certain challenges that are not posed in
adults like somatic growth, active life style, susceptibility to
infection and the generally anticipated long survival.
Permanent cardiac pacing in pediatric patients is performed
in few cardiology and cardiothoracic centers in Egypt. The aim
of the current study is to present our institute’s experience in
pediatric and adolescent pacemaker implantation and long-
term outcome.2. Methods
Between 1996 and 2010, thirty-two pediatric patients who
underwent permanent pacing were recorded and followed up
at outpatient pacemaker follow up clinics of Cardiology
Department, Ain Shams University. The techniques used for
the ﬁrst PPM implantation were recorded whether it was endo-
cardial or epicardial. We also recorded any complications dur-
ing the follow-up and the change of the pacing system or the
pacing mode.
2.1. Deﬁnitions
Battery replacement was deﬁned as the placement of a new
pulse generator only, while PPM replacement was deﬁned as
the placement of a new pulse generator and one or more
pacing lead(s) with abandonment of old pacing leads. Compli-
cations reported during follow up period were divided into two
categories: Lead related complications which are related to
mechanical or functional failure, and non-lead related
complications.
2.2. Implantation techniques
Endocardial or epicardial pacing was chosen according to the
presence of complex congenital heart disease, type of correc-
tive surgery and/or the size of the patient. Epicardial pacing
was preferred in children of small size, in the presence of intra-
cardiac right-to-left shunt or single ventricle physiology,
concomitant heart surgery, or lack of venous access to the
heart chambers.1 The majority of procedures were performed
under general anaesthesia. Antibiotic prophylaxis was rou-
tinely given perioperatively to all patients.2.3. Endocardial pacing
The endocardial leads were inserted via percutaneous puncture
of the right or left (rarely) subclavian vein. Active ﬁxation at-
rial leads were screwed into the right atrial appendage (RAA)
or right atrial (RA) free wall in case of inability to implant in
RAA. Ventricular leads were placed in the non-systemic ven-
tricular apex or outﬂow tract using passive or active ﬁxation
leads. An atrial loop (complete or incomplete)2 was attempted
in all patients to allow for somatic growth. Acute pacing
thresholds (measured with a pulse width of 0.50 ms at implan-
tation), impedances, and sensing of spontaneous atrial or ven-
tricular electrograms were evaluated during the implantation
procedure.
2.4. Epicardial pacing
The PPM pulse generator was placed in the abdominal wall in a
subcutaneous or submuscular (generally in infants) pockets.
The leads were inserted by standard surgical techniques either
through sternotomy or lateral thoracotomy. Epicardial leads
were regularly placed on the RA and the right (or left)
ventricle.3
2.5. Follow up
All patients were followed up every 3–6 months at the outpa-
tient pacemaker follow up clinics. Follow up included clinical
examination, interrogation of the device with regular measure-
ment of pacing thresholds, ventricular and atrial spontaneous
electrogram amplitudes, lead impedances as well as lead and
battery longevities. The type and timing of complications were
reported.
2.6. Statistical analysis
Data were analyzed using the SPSS program version 15. Quan-
titative data were presented using the mean and standard devi-
ation or median, while qualitative data were presented in
frequencies and percentages. Correlation of data was analyzed
using the Pearson correlation coefﬁcient. The Kaplan–Meier
method was used to study the longevity of the batteries and
leads.3. Results
3.1. Demographic and clinical characteristics atﬁrst implantation
Between 1996 and 2010, thirty-two patients underwent ﬁrst
PPM implantation including 18 males and 14 females, with
Table 1 Demographic and clinical characteristics at ﬁrst
implantation.
Demographic and clinical data n= 32
Age (years)
Range, median 0.16–15 (5)
Sex
Male (no., %) 18 (56.3%)
Female (no., %) 14 (43.7%)
BSA (m2)
Range, median 0.3–1.5 (0.7)
Weight (kg)
Range, mean ± SD 6–74 (21.6 ± 13.8)
Pacing indication (no., %)
Postoperative CHB 16 (50%)
Congenital AV block 13 (40.6%)
SND 3 (9.4%)
Heart disease (no., %) 25 (78.1%)
Surgically repaired VSD 13 (40.6%)
L-TGA 3 (9.4%)
Valvular PS 1 (3.1%)
Aortic CoA + subaortic membrane 1 (3.1%)
Repaired F4 1 (3.1%)
D-TGA 1 (3.1%)
Single ventricle (fontan) 2 (6.2%)
Repaired AV canal 1 (3.1%)
DCM 2 (6.2%)
BSA: Body surface area, CHB: Complete heart block, AV block:
Atrioventricular block, SND: Sinus node dysfunction, VSD: ven-
tricular septal defect, L-TGA: Levo-transposition of great arteries,
PS: pulmonary stenosis, CoA: coarctation of the aorta, F4: Fallot’s
tetralogy, D-TGA: Dextro-transposition of great arteries, DCM:
dilated cardiomyopathy.
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5.7 ± 3.8 years). Weight ranged between 6 and 74 kg (mean:
21.6 ± 13.8 kg). Body surface area (BSA) ranged between
0.3 and 1.5 m2 (median: 0.7 m2). Pacing indications were post-
operative complete heart block (CHB) in 16 patients (50%),
congenital AV block in 13 patients (40.6%), and symptomatic
sinus node dysfunction (SND) in three patients (9.4%). Seven
patients (21.8%) had structurally normal hearts, while 25
patients (78.1%) had congenital/structural heart disease (Table
1). Total number of procedures was 46 (1.4 per patient).
3.2. First implantation
The ﬁrst implanted pacing system was a VVI PM in eight cases
(25%), VVIR in 20 cases (62.5%), and DDD in four cases
(12.5%). Endocardial pacing was performed in 21 patients
(65.6%), while epicardial pacing was performed in 11 patients
(34.4%). The smallest weight and BSA for endocardial pacing
reported were 12 kg and 0.3 m2, respectively.
3.3. Second procedure
Eleven patients (34.3%) required a 2nd procedure within
0.5–11 years from 1st implantation. Six patients underwent
battery replacement as a 2nd procedure due to reaching bat-
tery elective replacement indicator (ERI) or end of life(EOL) in four patients, and for impending skin erosion in
the remaining two patients. PPM replacement was performed
in two patients (for battery ERI plus ventricular and atrial lead
fractures which necessitated replacement in one patient and for
skin erosion in the other patient). One patient had ventricular
lead repositioning after early lead dislodgement. Switch from
epicardial to endocardial pacing was performed as a 2nd
procedure in two patients (due to battery depletion and lead
insulation break in one patient and due to battery ERI with
system upgrade from VVIR to DDD in the other patient).
3.4. Third procedure
Three patients (9.3%) required 3rd procedure within 0.5–
8 years from 2nd procedure. One patient needed pacing system
upgrade from VVI to DDD with ventricular lead replacement
due to lead fracture. One patient required ventricular lead
replacement due to failure of capture. The third patient had
battery replacement due to battery ERI (Table 2).
3.5. Implantable generators
A total of 44 batteries were implanted during the period of
study. Table 3 shows battery manufacturers and models used
in the study population.
3.6. Pacing leads
A total of 46 leads were implanted during the period of the
study (thirty-six were implanted during 1st procedure);
thirty-one leads were endocardial (15 passive and 16 active
ﬁxation), and 15 leads were epicardial.
All epicardial and endocardial leads were steroid eluting.
Failures that necessitated re-intervention occurred in six leads
(13%); three endocardial and three epicardial leads. Mechani-
cal failure (fracture/insulation break/dislodgement) occurred
in two endocardial leads and three epicardial leads, while func-
tional failure (pacing malfunction) occurred in one endocardial
lead. The proportions of lead failure in endocardial versus epi-
cardial leads were not statistically signiﬁcant (p= 0.37).
Furthermore, three more epicardial leads showed mechani-
cal and functional problems including insulation break in one
lead and sensing malfunction (R wave <5 mV) in two leads.
These problems did not require re-intervention.
3.7. Follow up
Follow up duration ranged from 0.25 to 14 years (Median:
2.5 years). Patients with suboptimal pacing parameters or pac-
ing system failure were deﬁned by one or more of the follow-
ing: (1) Pacing failure: Failure of capture at the highest pulse
amplitude and/or pulse width. (2) Pacing threshold
>2 V± lead impedance > 1500 Ohm. (3) P/R wave mal-
sensing (P wave <1.5 mV, R wave <5 mV). (4) Battery lon-
gevity <1 year.
Patients’ group with suboptimal pacing parameters/pacing
system failure during follow up included 12 patients (37.5%),
with median age of 4 years (range: 0.16–8 years), mean weight
of 14.5 ± 5.8 kg, and median BSA of 0.62 m2 (range:
0.31–0.93 m2) at 1st implantation. Patients’ group with opti-
mal pacing parameters included 20 patients, with median age
of 6.2 years (range: 0.75–15 years), mean weight of
Table 3 Implantable generators used in study population.
Manufacturer Model Number
St. Jude Medical MICRONY SR+ 2425T 1
MICRONY II SR 2525T 12
Verity ADx XL SR 5156 1
Regency SCX 2408L 1
Medtronic SIGMA SSR 303 7
SIGMA SSR 203 4
SIGMA TM SWI 103 2
Relio 1
PRODIGY S 8164 1
En pulse E2DR01 2
Biotronic Pikos 01 1
Talos SR 2
Axios SR 1
Talos D 1
Talos DR 1
Vitatron Vita2 1
TOPAZ 3 SSIR 1
Telectronics Reﬂex model 8218 1
Ela-Sorin SORIN Diapason 1
NEWAY DR 1
Guidant INSIGNIA I AVT 1
Table 2 Types and indications of second and third procedures.
Type of procedure
(n= number of patients)
Indications of procedure Endocardial
pacing (n, %)
Epicardial
pacing (n, %)
Duration (years) from the
previous implantation
Battery replacement n= 7 Battery ERI/EOL.
Impending skin erosion
2 (6.2%)
2 (6.2%)
3 (9.3%) 2–8
2,5
PM upgrading (VVI to
DDD) with ventricular lead
replacement n= 1
Lead fracture 1 (3.1%) 6
Pacing system replacement
n= 2
Battery depletion + lead
fracture (atrial and
ventricular). Skin erosion
1 (3.1%) 1 (3.1%) 5
3
Lead repositioning n= 1 Lead dislodgement 1 (3.1%) 0.5
Lead replacement n= 1 Lead failure (failure of
capture)
1 (3.1%) 0.5
Switch from epicardial to
endocardial pacing n= 2
Battery
depletion + insulation
break. Battery ERI with PM
upgrade to DDD
1 (3.1%)
1 (3.1%)
2
11
ERI: elective replacement indicator, EOL: end of life.
186 R. Samir et al.23.2 ± 11.6 kg, and median BSA of 0.82 m2 (range: 0.33–
1.4 m2). Age, weight, and BSA were signiﬁcantly lower in pa-
tients with suboptimal pacing parameters/pacing system fail-
ure than that of patients with optimal pacing parameters
(p= 0.048, 0.023, and 0.032, respectively). No otherwise dif-
ference between the two groups as regards gender, presence
of heart disease, pacing approach, passive or active-ﬁxation
leads, and ventricular lead looping (Table 4).
3.8. Pacemaker dependency
At 3–6 months follow up; 15 patients (46.8%) were PPM
dependent with complete absence of intrinsic R waves. Among
these patients, 14 patients (93.3%) had CHD while one patient
(6.6%) had structurally normal heart, and 10 patients (66.6%)
had post operative CHB while 5 patients (33.3%) had congen-
ital AV block.
3.9. First battery longevity
The overall longevity of PPM batteries, independently from
pacing mode and battery manufacturer is presented by Kap-
lan–Meier survival estimate curve (Fig. 1). At 50 months
75% of batteries were still functioning, and the proportion
decreased to 60% at 125 months.
3.10. First ventricular lead longevity
The overall longevity of RV leads, independently from pacing
approach is represented by Kaplan–Meier survival estimate
curve (Fig. 2A). At 50 months 85% of leads were still func-
tioning and the proportion decreased to 63% at 125 months.
No signiﬁcant difference in ventricular lead longevity between
endocardial and epicardial leads (p= 0.38, Fig. 2B).
3.11. Complications
A total of 12 patients (37.5%) developed complications during
the period of the study. Lead related complications or failures
occurred in six patients (18.7%), while non-lead related compli-cations occurred in six patients (18.7%). Non-lead related com-
plications included skin erosion in three patients at
2.92 ± 1.82 years follow up. One patient had pectoral muscle
twitching that was managed by decreasing pacing amplitude
and pulse width from 3.5 V at 0.49 ms to 2.5 V at 0.43 ms.
One patient (with VVI PPM) developed atrial ﬂutter at
1.7 years from implantation that was managed by electrical car-
dioversion. One patient had keloid formation at healing site.
4. Discussion
Children represent a unique subset of patients with special
characteristics including anatomical variations depending on
Figure 1 Cumulative survival of PPM batteries in overall study
population.
Table 4 Patients with suboptimal pacing parameters/pacing system failure compared to patients with optimal pacing parameters
during follow up.
Suboptimal pacing parameters/
pacing system failure (n= 12)
Optimal pacing
parameters (n= 20)
P-value
Median age (yrs) 4 6.2 0.048
Mean weight (kg) 14.5 ± 5.8 23.2 ± 11.6 0.023
Median BSA (m2) 0.62 0.82 0.032
Sex (M/F) 9,3 9,11 0.147
Heart disease (no.) 11 14 0.16
Pacing approach (no.) (endocardial/epicardial) 6, 6 15, 5 0.25
Atrial lead (no.) (passive, active, epicardial) 0, 0, 1 0,2,1 1.00
Ventricular lead (no.) (passive, active, epicardial) 4, 2, 6 11, 4, 5 0.39
Looping of ventricular lead (no.) 12 17 0.48
BSA: body surface area, M: males, F: females.
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higher frequency of infections and traumatic events making
them more prone to complications. Still, pacemaker implanta-
tion in children and adolescents is a procedure with a generally
favorable outcome.
The indications for pacing in children and patients with
CHD are slightly different than in adults, mainly reﬂecting
the broad range of ages and concomitant structural heart dis-
ease involved.4 The natural history of bradyarrhythmias in
these palliated or repaired CHD patients and the speciﬁcs of
the surgical approach are major determinants inﬂuencing the
need for pacing.
In our series, a big proportion of patients (72%) had
CHD and 50% of patients had postoperative CHB. These
results are in line with the observations of other studies.3,5
Epicardial pacing is usually established because of either
cardiac anatomy or small body size.6,7 In our series, epicardial
pacing was only limited to small children (<12 kg body
weight, <0.3 m2 BSA), single ventricle physiology, or early
postoperative CHB. The smallest size for uncomplicated endo-
cardial pacing was a body weight of 12 kg and BSA of 0.3 m2
due to our concern about the development of venous thrombo-
sis, which results from disproportion between vessel and lead
size in smaller patients. Because of this consideration also,
we used purely ventricular pacing mode in transvenous pacing
in our series.
Despite recent technical progress, pacing leads remain the
‘weakest link’ of the permanent pacing system,8 especially in
a growing patient. Moreover, in the era of modern PPM tech-
nology, the reported complication rate in pediatric patients is
still high being around 10–30%2,3,9–11 compared to a 14%
reported complication rate in adults.12 Therefore, concerns
are raised about the long-term efﬁcacy and safety of endocar-
dial and epicardial pacing leads in children in terms of high
rate of lead abandonment.13
In our series the complication rate was 37.5% and half of
which were lead related complications or failures that necessi-
tated re-intervention and lead abandonment in the majority of
cases. In lead related complications or failures, 83.3% were
mechanical lead complications including lead dislodgement,
fractures and insulation breaks. Lead failures occurred in
9.6% of endocardial leads and in 20% of epicardial leads.
Other authors have described almost similar rates of lead
failures.1,3,5,14The relatively high failure rate of epicardial leads is related
not only to fracture due to somatic growth or traction imposed
on epicardial leads by thoraco-abdominal movement but also
to insulation break. Although all epicardial leads in our series
were steroid eluting still a rather high failure rate was reported.
The difference in failure rates between endocardial and epicar-
dial leads did not reach statistical signiﬁcance in our series.
Although it almost matches the rates reported by other
authors, this could be explained by the small total number of
both endocardial and epicardial leads.
No endocardial lead insulation break or mal-sensing were
detected in our experience whereas, insulation break and sens-
ing mal-function were detected in 26.6% of epicardial leads.
Non-lead related complications were only seen in endocardial
devices; late skin erosions (at 2.92 ± 1.82 years follow up) had
an incidence of 9.4% in our series compared to 2% incidence
reported by other authors,3,5 which may be due to the small
sample size of our study. Neither PPM pocket infection nor
deaths were reported in our series.
During the period of follow up, patients with suboptimal
pacing parameters when added to patients with pacing system
failures represented 37.5% of our patient’s population. When
Figure 2 (A) Ventricular lead survival in overall study population, (B) Endocardial versus epicardial ventricular lead survival (log-rank
test v2 = 0.76, p= 0.38).
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smooth follow up, only younger and smaller children had
higher incidence of suboptimal pacing parameters or pacing
system failures with no difference between endocardial and
epicardial implants. This suggests that age and size of the child
play a pivotal role in the long-term outcome of the device
whether it is endocardial or epicardial.
At follow up, 15 patients were PPM dependent, the major-
ity of whom (14 patients) had heart disease and two-thirds had
post operative CHB. This may indicate that the presence of
heart disease and operative trauma resulted in distal block that
is associated with more pacing dependency.
In our series, the longevity of steroid eluting epicardial
leads was comparable to that of endocardial leads which is
different from what is reported by some other authors,
who reported better survival of endocardial leads over
epicardial leads.3,5,10 This could be explained by the fact that
the majority of epicardial leads used in these studies were
non-steroid eluting leads, which were proved to have worse
outcomes, and when they compared steroid eluting epicar-
dial leads to conventional endocardial leads in one of these
studies they showed comparable survival3 as shown in our
study.
From this study we have learnt that careful and complete
follow-up evaluation is extremely useful, because the experi-
ence acquired and the knowledge of the complications that
have occurred may help in the understanding of how to pace
this population and help in new decision-making processes.
The continuing technical innovations can make accumulated
experience in a particular procedure quickly redundant and de-
mand new experience perhaps on a better basis. This makes
pediatric pacing more difﬁcult, but also more interesting and
challenging.
5. Limitations
The study is a single centre study and the number of patients is
relatively small.6. Conclusion
Permanent pacing in pediatric patients is generally safe and has
a favorable long-term outcome, but there remains a high rate of
complications, mainly related to leads. This is of particular
concern in children who need a lifetime of pacing. With modern
technology,15 transvenous and epicardial pacing are initially
comparable. In the older child or in the adolescent, endocardial
pacing should be considered to be the ﬁrst choice.
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